Views

CrossRef citations to date

Altmetric

Reports

Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung

Ben W.R. BalzerSydney Children’s Hospital, Randwick, New South Wales, Australia; ;School of Women’s and Children’s Health, University of New South Wales, Randwick, New South Wales, Australia;

http://orcid.org/0000-0001-7116-2339 View further author information

Christine LooDepartment of Anatomical Pathology, NSW Health Pathology, Prince of Wales Hospital, Randwick, New South Wales, Australia; View further author information

Eva A. WegnerDepartment of Nuclear Medicine and PET, Prince of Wales Hospital, Randwick, New South Wales, Australia; ;Prince of Wales Clinical School, University of New South Wales, Randwick, New South Wales, Australia; View further author information

Christa E. NathDepartment of Biochemistry, The Children’s Hospital at Westmead, Westmead, New South Wales, Australia; ;Faculty of Pharmacy, University of Sydney, Camperdown, New South Wales, Australia;

http://orcid.org/0000-0002-1013-3646 View further author information

Samiuela LeeDepartment of Biochemistry, The Children’s Hospital at Westmead, Westmead, New South Wales, Australia; View further author information

Chantelle SmithPharmacy Department, Sydney Children’s Hospital, Randwick, New South Wales, Australia; View further author information

Craig R. LewisPrince of Wales Clinical School, University of New South Wales, Randwick, New South Wales, Australia; ;Department of Medical Oncology, Prince of Wales Hospital, Randwick, New South Wales, Australia; View further author information

Toby N. TrahairSydney Children’s Hospital, Randwick, New South Wales, Australia; ;School of Women’s and Children’s Health, University of New South Wales, Randwick, New South Wales, Australia; ;Sydney Children’s Hospital, Kids Cancer Centre, Randwick, New South Wales, Australia;

http://orcid.org/0000-0002-3295-228X View further author information

Antoinette C. AnazodoSydney Children’s Hospital, Randwick, New South Wales, Australia; ;School of Women’s and Children’s Health, University of New South Wales, Randwick, New South Wales, Australia; ;Sydney Children’s Hospital, Kids Cancer Centre, Randwick, New South Wales, Australia; ;Prince of Wales Hospital, Nelune Comprehensive Cancer Centre, Randwick, New South Wales, AustraliaCorrespondence[email protected]

http://orcid.org/0000-0002-5495-6062 View further author information

show all

Abstract

Anaplastic lymphoma kinase (ALK) inhibitors such as crizotinib and alectinib have been shown to have significant activity in ALK-rearranged non-small cell lung cancers (NSCLC). There are no data for alectinib’s safety or efficacy in younger patients, though it is superior to crizotinib in adult trials. We present a 14-year old girl diagnosed with stage IV-B ALK-positive adenocarcinoma of the lung after presenting with cough and fever. She was commenced on alectinib at adult dose and has had sustained complete metabolic remission for 9 months. She is the youngest patient with lung adenocarcinoma to be treated with alectinib.

Keywords:

Acknowledgements

We wish to acknowledge the assistance of Professor Anthony Gill for providing the ALK-1 immunoperoxidase stain and his input in the diagnosis.

Conflicts of interest

The authors have no conflicts of interest to disclose.

Additional information

Funding

Dr Samiuela Lee is supported by a Project Grant Number 5 from The Kids Cancer Alliance (KCA), a translational cancer research center of The Cancer Institute of NSW. Dr Christa E. Nath is supported by the Leukaemia Research Support Fund of The Children’s Hospital Westmead. These funding bodies did not have any input in the design, conduct or preparation of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung

Information for

Open access

Opportunities

Help and information

Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung

Abstract

Acknowledgements

Conflicts of interest

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature